Vir Biotechnology (VIR) Operating Income (2018 - 2026)
Vir Biotechnology (VIR) posted Operating Income of -$132.3 million for Q1 2026, down 176.06% sequentially from -$47.9 million in Q4 2025, and up 5.2% YoY from -$125.8 million in Q1 2025.
Vir Biotechnology (VIR) Operating Income (2018 - 2026) Analysis & Trends
Vir Biotechnology has reported Operating Income for 9 years, with the latest figure at -$132.3 million in Q1 2026.
- Quarterly Operating Income rose 5.2% year-over-year to -$132.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$472.1 million (up 27.0% YoY) and the FY2025 annual result came in at -$479.3 million, up 18.37% from the prior year.
- Operating Income retreated to -$132.3 million in Q1 2026 per VIR's latest filing, from -$47.9 million in the prior quarter.
- Over five years, Operating Income peaked at $1.0 billion in Q1 2022 and troughed at -$231.3 million in Q3 2024.
- A 5-year average of -$61.8 million and a median of -$139.5 million in 2025 frame the typical range for Operating Income.
- The widest YoY moves for Operating Income: up 739.1% in 2022, down 469.11% in 2022.
- Over 5 years, Operating Income stood at -$150.5 million in 2022, then advanced by 7.63% to -$139.0 million in 2023, then rose by 15.73% to -$117.2 million in 2024, then surged by 59.09% to -$47.9 million in 2025, then sank by 176.06% to -$132.3 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$132.3 million, -$47.9 million, and -$173.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn | 73.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 73.47 Mn |
| Mar 31, 2026 | -132.29 Mn |
| Dec 31, 2025 | -47.92 Mn |
| Sep 30, 2025 | -173.44 Mn |
| Jun 30, 2025 | -118.42 Mn |
| Mar 31, 2025 | -139.55 Mn |
| Dec 31, 2024 | -117.15 Mn |
| Sep 30, 2024 | -231.30 Mn |
| Jun 30, 2024 | -158.63 Mn |
| Mar 31, 2024 | -80.08 Mn |
| Dec 31, 2023 | -139.02 Mn |
| Sep 30, 2023 | -186.73 Mn |
| Jun 30, 2023 | -215.19 Mn |
| Mar 31, 2023 | -143.37 Mn |
| Dec 31, 2022 | -150.50 Mn |
| Sep 30, 2022 | 194.96 Mn |
| Jun 30, 2022 | -225.22 Mn |
| Mar 31, 2022 | 1.01 Bn |
| Dec 31, 2021 | 571.75 Mn |
| Sep 30, 2021 | -53.39 Mn |